MARKET

RVNC

RVNC

Revance Therapeu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.37
-1.22
-7.83%
After Hours: 14.37 0 0.00% 16:01 05/18 EDT
OPEN
15.14
PREV CLOSE
15.59
HIGH
15.52
LOW
14.10
VOLUME
721.30K
TURNOVER
913.46K
52 WEEK HIGH
33.83
52 WEEK LOW
11.65
MARKET CAP
1.05B
P/E (TTM)
-3.5613
1D
5D
1M
3M
1Y
5Y
Bullish insiders bet US$1.0m on Revance Therapeutics, Inc. (NASDAQ:RVNC)
Multiple insiders secured a larger position in Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shares over the last 12...
Simply Wall St. · 1d ago
Recap: Revance Therapeutics Q1 Earnings
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/10 22:21
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:45
BRIEF-Revance Reports Q1 2022 Financial Results
reuters.com · 05/10 21:17
Revance Therapeutics Q1 EPS $(0.94) Misses $(0.91) Estimate, Sales $25.30M Beat $24.01M Estimate
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.91) by 3.3 percent. This is a 12.96 percent increase over losses of $(1.08) per share
Benzinga · 05/10 20:19
Revance Therapeutics GAAP EPS of -$0.94 beats by $0.02, revenue of $25.26M beats by $1.39M
Revance Therapeutics press release (NASDAQ:RVNC): Q1 GAAP EPS of -$0.94 beats by $0.02. Revenue of $25.26M (+89.9% Y/Y) beats by $1.39M.
Seekingalpha · 05/10 20:15
-- Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $25.3M, vs. Street Est of $23.9M
MT Newswires · 05/10 16:44
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
More
No Data
Learn about the latest financial forecast of RVNC. Analyze the recent business situations of Revance Therapeu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

30.00%Strong Buy
60.00%Buy
10.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RVNC stock price target is 28.78 with a high estimate of 55.00 and a low estimate of 17.00.
High55.00
Average28.78
Low17.00
Current 14.37
EPS
Actual
Estimate
-0.92-0.69-0.46-0.23
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 207
Institutional Holdings: 60.96M
% Owned: 85.34%
Shares Outstanding: 72.77M
TypeInstitutionsShares
Increased
56
8.09M
New
34
1.56M
Decreased
41
6.55M
Sold Out
36
4.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Non-Executive Chairman/Independent Director
Angus Russell
President
Dustin Sjuts
Chief Executive Officer/Director
Mark Foley
Chief Financial Officer
Tobin Schilke
Senior Vice President/General Counsel/Secretary
Dwight Moxie
Independent Director
Jill Beraud
Independent Director
Julian Gangolli
Independent Director
Carey Kolaja
Independent Director
Chris Nolet
Independent Director
Philip Vickers
Independent Director
Olivia Ware
No Data
No Data
About RVNC
Revance Therapeutics, Inc. is a biotechnology company that is focused on aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines, and crow’s feet, as well as in two therapeutic indications cervical dystonia and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for the correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription, and loyalty digital services.

Webull offers kinds of Revance Therapeutics Inc stock information, including NASDAQ:RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.